SCHWARZ PHARMA


Company


Research & Development


Products


Investor Relations


Job Service


Press Room


Service
> Half Year Report 2008
Revenues: €196.7 million ( 8.3%) / Operating result: -€16.5 million; net result: -€27.4 million / Outlook for 2008 / R&D: Neupro® (RLS) and Vimpat® (epilepsy) recommended for marketing approval
more


> Three Months Report 2008
SCHWARZ PHARMA gets off to a good start
more


> Full Year Report 2007
Integration of SCHWARZ PHARMA Business into UCB Group on Target
more


>



Home


Contact


Imprint